Earnings Call Insights: Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Christophe Weber, CEO, announced his ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process. The two terminations, coupled to the ...

Takeda could acquire next-generation immunotherapies as it seeks to broaden its offering in the hyper-competitive field of cancer treatment. The Japanese pharma has been building a presence in ...

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts.

Investors might want to bet on Takeda Pharmaceutical Co. (TAK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

As of 2:11:17 PM EDT. Market Open. OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2025--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase ...